Related Experiment Video
Updated: Apr 19, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
[Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer]
Abstract:
Because of recent advances in the field of nucleic-acid chemistry, antisense oligodeoxynucleotide (AS ODN) technology can offer an attractive strategy to specifically inhibit expression of target genes causing a wide variety of diseases, including cancers. In prostate cancer (PC), several genes, involved in the acquisition of castration-resistant (CR) phenotype, have been identified, some of which, such as clusterin and heat shock protein 27, are intensively investigated as optimal targets for AS ODN therapy. In this review, we attempted to summarize the progress in the novel therapeutic strategy using AS ODN against CRPC, and to discuss the data of the recently completed and currently conducting clinical trials using AS ODNs as well as the future prospects of this therapy for treating CRPC.
Insights
Antisense oligodeoxynucleotide (AS ODN) therapy shows promise for treating advanced prostate cancer by targeting specific genes. This review summarizes AS ODN progress and clinical trial data for castration-resistant prostate cancer (CRPC).
Area of Science:
- Nucleic acid chemistry
- Molecular biology
- Oncology
Context:
- Prostate cancer (PC) progression to castration-resistance (CR) involves specific gene expression.
- Clusterin and heat shock protein 27 are key targets in CRPC.
- Antisense oligodeoxynucleotide (AS ODN) technology offers targeted gene silencing.
Purpose:
- To review the therapeutic strategy of AS ODN for castration-resistant prostate cancer (CRPC).
- To discuss current and completed clinical trial data for AS ODN in CRPC.
- To explore future prospects of AS ODN therapy for CRPC.
Summary:
- Recent advances in nucleic acid chemistry enable AS ODN technology for specific gene expression inhibition.
- AS ODN therapy is being investigated for CRPC, targeting genes like clusterin and heat shock protein 27.
- This review consolidates progress, clinical trial outcomes, and future potential of AS ODN for CRPC.
Impact:
- AS ODN therapy presents a novel strategy for treating difficult-to-treat prostate cancers.
- Clinical trial data will inform the efficacy and safety of AS ODNs in CRPC patients.
- This research paves the way for personalized gene-targeted therapies in oncology.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...